Nat Clin Pract Endocrinol Metab. 2007 Dec;3(12):798-9. Epub 2007 Sep 11.

Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?

Source

Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, ON, Canada. gerstein@mcmaster.ca

Comment on

N Engl J Med. 2007 Jun 14;356(24):2457-71.

PMID:: 17848926; [PubMed]

Publication Types

Comment

LinkOut - more resources

Full Text Sources

Nature Publishing Group

Other Literature Sources

COS Scholar Universe

Supplemental Content

Save items

Related citations in PubMed

Review Cardiovascular risk and cardiometabolic protection: role of glitazones. [J Nephrol. 2008]
Review Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C. J Nephrol. 2008 Nov-Dec; 21(6):826-35.
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. [Lancet. 2009]
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Team. Lancet. 2009 Jun 20; 373(9681):2125-35. Epub 2009 Jun 6.
Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. [Metabolism. 2007]
Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Metabolism. 2007 Oct; 56(10):1396-401.
Review [Therapy with glitazones--a risk for cardiovascular disease?]. [Dtsch Med Wochenschr. 2007]
Review [Therapy with glitazones--a risk for cardiovascular disease?].
Rottlaender D, Michels G, Erdmann E, Hoppe UC. Dtsch Med Wochenschr. 2007 Dec; 132(49):2629-32.
Review The rough road for rosiglitazone. [Curr Opin Endocrinol Diabetes ...]
Review The rough road for rosiglitazone.
Goldfine AB. Curr Opin Endocrinol Diabetes Obes. 2008 Apr; 15(2):113-7.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Does treatment with rosiglitazone increase cardiovascular risk of patients with ...
Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?
Nat Clin Pract Endocrinol Metab. 2007 Dec ;3(12):798-9. Epub 2007 Sep 11 .

PubMed
Medullary impairment at early stage of non-traumatic osteonecrosis of the femora...
Medullary impairment at early stage of non-traumatic osteonecrosis of the femoral head.
Rheumatol Int. 1991 ;11(4-5):215-7.

PubMed
Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial i...
Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department.
Pediatr Infect Dis J. 2007 Aug ;26(8):672-7.

PubMed
Exercise and heart transplantation. A review.
Exercise and heart transplantation. A review.
Sports Med. 1991 Dec ;12(6):359-79.

PubMed
Diet and body composition. Effect of very low calorie diets and exercise.
Diet and body composition. Effect of very low calorie diets and exercise.
Sports Med. 1991 Oct ;12(4):237-49.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?

Source

Comment on

Publication Types

Publication Types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information